The Acute Haemodynamic Effect of Nebulised Frusemide in Stable, Advanced Heart Failure

Heart Lung and Circulation

Volumn 21, Issue 5, 2012, Pages 260-266

  Newton, Phillip J ^a,b   Davidson, Patricia M ^a,c   Krum, Henry ^d   Ollerton, Richard ^b   Macdonald, Peter ^e,f  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c St Vincent's and Mater Health   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e ST VINCENT S HOSPITAL   (Australia)

^f VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Frusemide; Haemodynamics; Heart failure

Indexed keywords

FUROSEMIDE; PLACEBO;

ADULT; ADVANCED HEART FAILURE; ARTICLE; BLADDER; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; HUMAN; LUNG ARTERY PRESSURE; LUNG PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NEBULIZATION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; URINE VOLUME;

ACUTE DISEASE; CARDIAC CATHETERIZATION; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FUROSEMIDE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; STATISTICS, NONPARAMETRIC;

EID: 84861201429     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2012.03.002     Document Type: Article

References (29)

1. Janssen D.J.A., Spruit M.A., Wouters E.F.M., Schols J. Daily symptom burden in end-stage chronic organ failure: a systematic review. Palliat Med 2008, 22:938-948.
2. Poole-Wilson P.A., Swedberg K., Cleland J.G.F., Di Lenarda A., Hanrath P., Komajda M., et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003, 362:7-13.
3. Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G.F., Horowitz J.D., Massie B.M., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312-2318.
4. Pfeffer M.A., Swedberg K., Granger C.B., Held P., McMurray J.J.V., Michelson E.L., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003, 362:759-766.
5. Cleland J.G.F., Daubert J.-C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005, 352:1539-1549.
6. Bianco S., Pieroni M.G., Refini R.M., Rottoli L., Sestini P. Protective effect of inhaled furosemide on allergen-induced early and late asthmatic reactions. N Engl J Med 1989, 321:1069-1073.
7. Newton P.J., Davidson P.M., Macdonald P., Ollerton R., Krum H. Nebulized furosemide for the management of dyspnea: does the evidence support its use?. J Pain Symptom Manage 2008, 36:424-441.
8. Elwood W., Lotvall J.O., Barnes P.J., Chung K.F. Loop diuretics inhibit cholinergic and noncholinergic nerves in guinea pig airways. Am Rev Respir Dis 1991, 143:1340-1344.
9. Lockhart A., Slutsky A.S. Furosemide and loop diuretics in human asthma. Chest 1994, 106:244-249.
10. Verleden G.M., Pype J.L., Deneffe G., Demedts M.G. Effect of loop diuretics on cholinergic neurotransmission in human airways in vitro. Thorax 1994, 49:657-663.
11. Freed A.N., Taskar V., Schofield B., Omori C. Effect of furosemide on hyperpnea-induced airway obstruction, injury, and microvascular leakage. J Appl Physiol 1996, 81:2461-2467.
12. Lundergan C.F., Fitzpatrick T.M., Rose J.C., Ramwell P.W., Kot P.A. Effect of cyclooxygenase inhibition on the pulmonary vasodilator response to furosemide. J Pharmacol Exp Ther 1988, 246:102-106.
13. Sudo T., Hayashi F., Nishino T. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats. Am J Respir Crit Care Med 2000, 162:971-975.
14. Kohara H., Ueoka H., Aoe K., Maeda T., Takeyama H., Saito R., et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003, 26:962-967.
15. Shimoyama N., Shimoyama M. Nebulized furosemide as a novel treatment for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002, 23:73-76.
16. Stone P., Kurowska A., Tookman A. Nebulized frusemide for dyspnoea. Palliat Med 1994, 8:258.
17. Stone P., Rix, Kurowska A., Tookman Re: nebulized furosemide for dyspnea in terminal cancer patients. J Pain Symptom Manage 2002, 24:274-275.
18. Wilcock A., Walton A., Manderson C., Feathers L., El Khoury B., Lewis M., et al. Randomised, placebo-controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008, 63:872-875.
19. Towers K.A., Bardsley K.A., Macdonald P.S. Nebulised frusemide for the symptomatic treatment of end-stage congestive heart failure. Med J Aust 2010, 193:555.
20. Hayward C.S., Rogers P., Keogh A.M., Kelly R., Spratt P.M., Macdonald P.S. Inhaled nitric oxide in cardiac failure: vascular versus ventricular effects. J Cardiovasc Pharmacol 1996, 27:80-85.
21. Gift A., Narsavage G. Validity of the numeric rating scale as a measure of dyspnea. Am J Crit Care 1998, 7:200-204.
22. Huang Y.-H., Bih L.-I., Chen S.-L., Tsai S.-J., Teng C.-H. The accuracy of ultrasonic estimation of bladder volume: a comparison of portable and stationary equipment. Arch Phys Med Rehabil 2004, 85:138-141.
23. Miniati D.N., Robbins R.C. Heart transplantation: a thirty-year perspective. Annu Rev Med 2002, 53:189-205.
24. McMurray J. Heart failure: we need more trials in typical patients. Eur Heart J 2000, 21:699-700.
25. Ventresca P.G., Nichol G.M., Barnes P.J., Fan Chung K. Inhaled furosemide inhibits cough induced by low chloride content solutions but not by capsaicin. Am Rev Respir Dis 1990, 142:143-146.
26. Foresi A., Pelucchi A., Mastropasqua B., Cavigioli G., Carlesi R.M., Marazzini L. Effect of inhaled furosemide and torasemide on bronchial response to ultrasonically nebulized distilled water in asthmatic subjects. Am Rev Respir Dis 1992, 146:364-368.
27. Yates D.H., O'Connor B.J., Yilmaz G., Aikman S., Worsdell M., Barnes P.J., et al. Effect of acute and chronic inhaled furosemide on bronchial hyperresponsiveness in mild asthma. Am J Respir Crit Care Med 1995, 152:2173-2175.
28. Rodríguez Vázquez J.C., Pino Alfonso P.P., Gassiot Nuño C., Paez Prats I., Fernández Manzano E. Assessment of the bronchodilator effect of inhaled furosemide compared to salbutamol in asthmatic patients. J Investig Allergol Clin Immunol 1998, 8:115-118.
29. Nichol G.M., Alton E.W.F.W., Nix A., Geddes D.M., Chung K.F., Barnes P.J. Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects. Am Rev Respir Dis 1990, 142:576-580.